Bluejay Diagnostics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Bluejay Diagnostics, Inc. (BJDX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $44.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-12
- Bluejay Diagnostics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $22.20K, a 7.72% increase year-over-year.
- Bluejay Diagnostics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $21.80K, a 34.92% decline year-over-year.
- Bluejay Diagnostics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $21.39K, a 20.82% increase year-over-year.
- Bluejay Diagnostics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $21.00K, a 41.52% decline year-over-year.
- Bluejay Diagnostics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $96.50K, a 21.85% decline from fiscal 2024.
- Bluejay Diagnostics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $123.48K, a 6.63% decline from fiscal 2023.
- Bluejay Diagnostics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $132.25K, a 11.70% decline from fiscal 2022.
- Bluejay Diagnostics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $149.77K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $44.00K 10-Q · filed 2026-08-12 | $65.39K derived: sum of 3 quarters · filed 2026-08-12 | $86.39K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $21.80K 10-Q · filed 2026-05-07 | $43.19K derived: sum of 2 quarters · filed 2026-05-07 | $64.19K derived: sum of 3 quarters · filed 2026-05-07 | $84.80K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $21.39K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $42.39K derived: sum of 2 quarters · filed 2026-03-06 | $63.01K derived: sum of 3 quarters · filed 2026-08-12 | $96.50K 10-K · filed 2026-03-06 |
| 2025-09-30 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $41.61K derived: sum of 2 quarters · filed 2026-08-12 | $75.11K 10-Q · filed 2025-11-07 | $92.81K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $20.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $54.10K 10-Q · filed 2026-08-12 | $71.81K derived: sum of 3 quarters · filed 2026-08-12 | $107.72K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $33.49K 10-Q · filed 2026-05-07 | $51.20K derived: sum of 2 quarters · filed 2026-05-07 | $87.11K derived: sum of 3 quarters · filed 2026-05-07 | $122.36K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $17.71K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $53.61K derived: sum of 2 quarters · filed 2026-03-06 | $88.87K derived: sum of 3 quarters · filed 2026-03-06 | $123.48K 10-K · filed 2026-03-06 |
| 2024-09-30 | $35.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $71.16K derived: sum of 2 quarters · filed 2025-11-07 | $105.77K 10-Q · filed 2025-11-07 | $139.75K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $35.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $69.86K 10-Q · filed 2025-08-07 | $103.85K derived: sum of 3 quarters · filed 2025-08-07 | $121.46K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $34.61K 10-Q · filed 2025-05-13 | $68.59K derived: sum of 2 quarters · filed 2025-05-13 | $86.20K derived: sum of 3 quarters · filed 2025-05-13 | $126.53K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $33.98K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $51.59K derived: sum of 2 quarters · filed 2025-03-31 | $91.92K derived: sum of 3 quarters · filed 2025-03-31 | $132.25K 10-K · filed 2025-03-31 |
| 2023-09-30 | $17.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $57.94K derived: sum of 2 quarters · filed 2024-11-07 | $98.27K 10-Q · filed 2024-11-07 | $136.51K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $40.33K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $80.66K 10-Q · filed 2024-08-14 | $118.90K derived: sum of 3 quarters · filed 2024-08-14 | $163.45K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $40.33K 10-Q · filed 2024-05-15 | $78.57K derived: sum of 2 quarters · filed 2024-05-15 | $123.13K derived: sum of 3 quarters · filed 2024-05-15 | $161.86K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $38.24K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $82.80K derived: sum of 2 quarters · filed 2024-03-28 | $121.53K derived: sum of 3 quarters · filed 2024-03-28 | $149.77K 10-K · filed 2024-03-28 |
| 2022-09-30 | $44.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $83.29K derived: sum of 2 quarters · filed 2023-11-09 | $111.53K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $38.73K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $66.97K 10-Q · filed 2022-08-10 | ||
| 2022-03-31 | $28.24K 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |